Tag Archives | fine chemicals

Not so fine anymore?

News is slowly trickling in of Indian pharmaceutical and fine chemical companies shutting down facilities that were acquired with great zeal during the 2005-08 overseas acquisition drive. Shasun has decided to shut its facility at Newbie in Scotland and is reportedly shifting manufacturing to other locations in the US, the UK and India. The Newbie […]

Continue Reading

Matrix mulls Docpharma sale

Have Indian fine chemical and pharma companies been too hasty in their global acquisitions? I had been hearing talk of some companies running into integration problems or having second thoughts on perceived benefits of their acquisitions. But today’s report that Matrix Labs is exploring sale of Docpharma suggests that there is some basis to all […]

Continue Reading

Testing times for CRAMS

Business is booming in India’s custom research and manufacturing services (CRAMS) industry thanks to the country’s strong process chemistry skills, low operational costs and the availability of a skilled workforce. Frost & Sullivan values the Indian CRAMS market at $890m, and expects it to expand by 40% in 2008. It estimates the market for outsourcing […]

Continue Reading

CRAMs comes with challenges

India’s success in the global custom research and manufacturing services space (CRAMS) is well documented. And the untapped potential is huge especially as western pharmaceutical companies remain under pressure to cut costs. According to one estimate, the global manufacturing outsourcing opportunity is likely to grow from US$20bn in 2006 to US$31bn in 2010. The global […]

Continue Reading

Indian chemicals score on CRAMS

Jubiliant Organosys’ announcement that it has clinched deals worth $60m from global life science majors reinforces India’s growing strength in the custom research and manufacturing services (CRAMS) business. Rising competition and research costs are supporting the CRAMS outsourcing wave and beneficiaries include Shasun Chemicals, Nicholas Piramal, Divis Lab and Dishman Pharma. A report in the […]

Continue Reading